Global Antibody Partnering 2010-2015: Deal trends, players and financials

Nov 10, 2015, 14:44 ET from Reportlinker

NEW YORK, Nov. 10, 2015 /PRNewswire/ -- The Global Antibody Partnering 2010-2015: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Antibodies
Antibody-drug conjugates
Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human mAb
Polyclonal Antibodies

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains a comprehensive listing of all antibody partnering deals announced since January 2010, including financial terms where available, including over 900 links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report takes readers through the antibody deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering antibody partnering deals.

The report presents average financial deal terms values for antibody deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the antibody partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 900 online deals records of actual antibody deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?


Finally the report concludes by looking into the future of antibody partnering. With so many innovators looking for the next big thing in the field, the report selects companies to watch who are predicted to become big in the field based on their current dealmaking and financial trends.

Throughout the report various tables, figures and graphs are embedded in order to illustrate the trends and partnering activities of the antibody field.

By the end of the report prospective dealmakers will have gained a thorough understanding of the partnering landscape of the antibody market and will be familiar with the values and structures of the deals being signed within it.

Report scope

Global Antibody Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to antibody trends and structure of deals entered into by leading companies worldwide.

Global Antibody Partnering 2010-2015 includes:

Trends in antibody dealmaking in the biopharma industry since 2009
Analysis of antibody deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life antibody deals
Access to over 900 antibody deal records and contract documents where available
The leading antibody deals by value since 2009
Most active antibody dealmakers since 2009
The leading antibody partnering resources

In Global Antibody Partnering 2010-2015, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Antibody Partnering 2010-2015 report provides comprehensive access to available deals and contract documents for over 900 antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise antibody rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?Global Antibody Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of antibody deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of antibody agreements with numerous real life case studies
Comprehensive access to over 900 actual antibody deals entered into by the world's biopharma companies, together with contract documents if available
Detailed access to actual antibody contracts enter into by the leading companies
Identify leading antibody deals by value since 2010
Identify the most active antibody dealmakers since 2010
Insight into the terms included in a antibody agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Read the full report: http://www.reportlinker.com/p03375617-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com